Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial
The Lancet Neurology2008Vol. 7(10), pp. 903–914
Citations Over TimeTop 1% of 2008 papers
Daniel D. Mikol, Frederik Barkhof, Peter Chang, Patricia K. Coyle, Douglas Jeffery, Steven R. Schwid, Bettina Stubinski, Bernard M.J. Uitdehaag
Related Papers
- → Glatiramer acetate–induced acute hepatotoxicity in an adolescent with MS(2013)34 cited
- → Ischemic skin necrosis caused by glatiramer acetate in multiple sclerosis patients(2014)2 cited
- → Glatiramer in the treatment of multiple sclerosis-0(2011)13 cited
- [Multiple sclerosis: current therapies and future perspectives].(2011)
- → Clinical course of multiple sclerosis in Japanese patients treated with glatiramer acetate(2017)